Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.22 USD | -3.17% | +3.39% | -18.67% |
04-09 | Transcript : Immunic, Inc. - Special Call | |
03-21 | Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium | MT |
Business Summary
Number of employees: 77
Managers
Managers | Title | Age | Since |
---|---|---|---|
Daniel Vitt
CEO | Chief Executive Officer | 55 | 16-12-31 |
Glenn Whaley
DFI | Director of Finance/CFO | 56 | 19-11-30 |
Hella Kohlhof
CTO | Chief Tech/Sci/R&D Officer | 51 | 16-12-31 |
Andreas Muehler
CTO | Chief Tech/Sci/R&D Officer | 60 | 16-07-31 |
Jessica Breu
IRC | Investor Relations Contact | - | - |
Patrick Walsh
PRN | Corporate Officer/Principal | 41 | 21-10-13 |
Inderpal Singh
LAW | General Counsel | 58 | 21-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Barclay Phillips
BRD | Director/Board Member | 61 | 19-11-18 |
Tamar Howson
BRD | Director/Board Member | 75 | 19-10-10 |
Jörg Neermann
BRD | Director/Board Member | 57 | 19-03-31 |
Daniel Vitt
CEO | Chief Executive Officer | 55 | 16-12-31 |
Duane Nash
CHM | Chairman | 53 | 18-12-31 |
Richard Rudick
BRD | Director/Board Member | 73 | 23-04-25 |
Monika Tornsen
BRD | Director/Board Member | 45 | 22-07-04 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 90,079,016 | 83,120,924 ( 92.28 %) | 0 | 92.28 % |
Company contact information
Immunic, Inc.
1200 Avenue of the Americas Suite 200
10036, New York
+
http://www.immunic-therapeutics.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.67% | 110M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- IMUX Stock
- Company Immunic, Inc.